Time Course of Kidney Injury Biomarkers in Children With Septic Shock: Nested Cohort Study Within the Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis Trial.

IF 4 2区 医学 Q1 CRITICAL CARE MEDICINE
Scott L Weiss, Julie C Fitzgerald, Benjamin L Laskin, Ruchi Singh, Amanda S Artis, Ananya Vohra, Elena Tsemberis, Emem Kierian, Kristen C Lau, Atzael B Campos, Christopher Hickey, Katie L Hayes, Daniel Singleton, Elliot Long, Franz E Babl, Stuart R Dalziel, Graham C Thompson, Stephen B Freedman, Michelle Eckerle, Robert W Hickey, Jing Huang, Nathan Kuppermann, Fran Balamuth
{"title":"Time Course of Kidney Injury Biomarkers in Children With Septic Shock: Nested Cohort Study Within the Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis Trial.","authors":"Scott L Weiss, Julie C Fitzgerald, Benjamin L Laskin, Ruchi Singh, Amanda S Artis, Ananya Vohra, Elena Tsemberis, Emem Kierian, Kristen C Lau, Atzael B Campos, Christopher Hickey, Katie L Hayes, Daniel Singleton, Elliot Long, Franz E Babl, Stuart R Dalziel, Graham C Thompson, Stephen B Freedman, Michelle Eckerle, Robert W Hickey, Jing Huang, Nathan Kuppermann, Fran Balamuth","doi":"10.1097/PCC.0000000000003737","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Severe acute kidney injury (AKI) portends poor outcomes in pediatric sepsis. We evaluated the trajectory and prognostic utility of AKI biomarkers in pediatric septic shock using a subset of participants in the ongoing Pragmatic Pediatric Trial of Balanced vs. Normal Saline Fluid in Sepsis (PRoMPT BOLUS) trial, NCT04102371. We tested whether fluid volume is associated with persistent elevation of urine neutrophil gelatinase-associated lipocalin (Ur-NGAL).</p><p><strong>Design: </strong>Prospective, non-prespecified cohort study within the PRoMPT BOLUS trial.</p><p><strong>Setting: </strong>Three children's hospitals in the United States.</p><p><strong>Patients: </strong>Four hundred seventy-eight patients aged 2 months to younger than 18 years old with septic shock.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Ur-NGAL, kidney injury molecule-1, liver fatty acid binding protein, and interleukin-18 and plasma cystatin C were collected at presentation (T1), days 2-3 (T2), and before discharge/death (T3). At presentation, 418 (88%) had no or only stage 1 AKI and 60 (12%) had stage 2/3 AKI defined using Kidney Disease Improving Global Outcomes creatinine thresholds. All biomarkers were higher with stage 2/3 compared with no/stage 1 AKI at T1 and T2, but only cystatin C remained higher at T3. Among patients with no/stage 1 AKI at presentation, those with Ur-NGAL greater than or equal to 150 vs. less than 150 ng/mL had fewer hospital-free days (21 [interquartile range (IQR) 15-24] vs. 23 d [IQR 19-25], p = 0.05). After applying inverse probability treatment weighting to balance covariates, 14% of patients who received greater than 100 mL/kg within 48 hours had persistently elevated Ur-NGAL over time compared with 6% who received 40-100 mL/kg (odds ratio 2.7 [95% CI, 1.1-6.2]). Hospital-free days were no different across fluid volume groups.</p><p><strong>Conclusions: </strong>Although kidney injury biomarkers mirrored serum creatinine in children with septic shock, elevated Ur-NGAL identified a subset with subclinical AKI with fewer hospital-free days despite no/stage 1 AKI by creatinine. Children receiving greater than 100 mL/kg fluid had greater odds of early and persistently elevated Ur-NGAL, suggesting high fluid volumes may perpetuate initial kidney damage.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Critical Care Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PCC.0000000000003737","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Severe acute kidney injury (AKI) portends poor outcomes in pediatric sepsis. We evaluated the trajectory and prognostic utility of AKI biomarkers in pediatric septic shock using a subset of participants in the ongoing Pragmatic Pediatric Trial of Balanced vs. Normal Saline Fluid in Sepsis (PRoMPT BOLUS) trial, NCT04102371. We tested whether fluid volume is associated with persistent elevation of urine neutrophil gelatinase-associated lipocalin (Ur-NGAL).

Design: Prospective, non-prespecified cohort study within the PRoMPT BOLUS trial.

Setting: Three children's hospitals in the United States.

Patients: Four hundred seventy-eight patients aged 2 months to younger than 18 years old with septic shock.

Interventions: None.

Measurements and main results: Ur-NGAL, kidney injury molecule-1, liver fatty acid binding protein, and interleukin-18 and plasma cystatin C were collected at presentation (T1), days 2-3 (T2), and before discharge/death (T3). At presentation, 418 (88%) had no or only stage 1 AKI and 60 (12%) had stage 2/3 AKI defined using Kidney Disease Improving Global Outcomes creatinine thresholds. All biomarkers were higher with stage 2/3 compared with no/stage 1 AKI at T1 and T2, but only cystatin C remained higher at T3. Among patients with no/stage 1 AKI at presentation, those with Ur-NGAL greater than or equal to 150 vs. less than 150 ng/mL had fewer hospital-free days (21 [interquartile range (IQR) 15-24] vs. 23 d [IQR 19-25], p = 0.05). After applying inverse probability treatment weighting to balance covariates, 14% of patients who received greater than 100 mL/kg within 48 hours had persistently elevated Ur-NGAL over time compared with 6% who received 40-100 mL/kg (odds ratio 2.7 [95% CI, 1.1-6.2]). Hospital-free days were no different across fluid volume groups.

Conclusions: Although kidney injury biomarkers mirrored serum creatinine in children with septic shock, elevated Ur-NGAL identified a subset with subclinical AKI with fewer hospital-free days despite no/stage 1 AKI by creatinine. Children receiving greater than 100 mL/kg fluid had greater odds of early and persistently elevated Ur-NGAL, suggesting high fluid volumes may perpetuate initial kidney damage.

脓毒性休克儿童肾损伤生物标志物的时间进程:在脓毒症试验中平衡生理盐水与生理盐水的实用儿科试验中的巢式队列研究
目的:严重急性肾损伤(AKI)预示着儿童败血症的不良预后。我们使用正在进行的脓毒症中平衡与生理盐水对比的实用儿科试验(PRoMPT BOLUS)试验(NCT04102371)的一组参与者,评估了AKI生物标志物在儿童脓毒症休克中的发展轨迹和预后效用。我们测试了液体容量是否与尿中性粒细胞明胶酶相关脂钙蛋白(Ur-NGAL)的持续升高有关。设计:在PRoMPT BOLUS试验中进行前瞻性、非预先指定队列研究。背景:美国的三家儿童医院。患者:478例2个月至18岁以下脓毒性休克患者。干预措施:没有。测量结果及主要结果:在患者出征时(T1)、2-3天(T2)和出院/死亡前(T3),分别采集u - ngal、肾损伤分子-1、肝脂肪酸结合蛋白、白细胞介素-18和血浆胱抑素C。报告时,418例(88%)没有或只有1期AKI, 60例(12%)有2/3期AKI,使用肾脏疾病改善全球结局肌酐阈值定义。T1和T2时,2/3期的所有生物标志物均高于无/ 1期AKI,但只有胱抑素C在T3时仍高于无/ 1期AKI。在首发时无/期AKI的患者中,Ur-NGAL≥150和小于150 ng/mL的患者免住院天数更少(21[四分位间距(IQR) 15-24]对23 d [IQR 19-25], p = 0.05)。在应用反概率治疗加权来平衡相关变量后,在48小时内接受大于100 mL/kg治疗的患者中,14%的患者随着时间的推移持续升高Ur-NGAL,而接受40-100 mL/kg治疗的患者中,这一比例为6%(优势比为2.7 [95% CI, 1.1-6.2])。不同液体容量组的无住院天数没有差异。结论:尽管肾损伤生物标志物反映了脓毒性休克儿童的血清肌酐,但升高的Ur-NGAL可以通过肌酐识别出亚临床AKI患者,尽管没有/期AKI,但无住院天数较少。接受超过100 mL/kg液体的儿童早期和持续升高Ur-NGAL的几率更大,这表明高液体容量可能使初始肾脏损害长期存在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pediatric Critical Care Medicine
Pediatric Critical Care Medicine 医学-危重病医学
CiteScore
7.40
自引率
14.60%
发文量
991
审稿时长
3-8 weeks
期刊介绍: Pediatric Critical Care Medicine is written for the entire critical care team: pediatricians, neonatologists, respiratory therapists, nurses, and others who deal with pediatric patients who are critically ill or injured. International in scope, with editorial board members and contributors from around the world, the Journal includes a full range of scientific content, including clinical articles, scientific investigations, solicited reviews, and abstracts from pediatric critical care meetings. Additionally, the Journal includes abstracts of selected articles published in Chinese, French, Italian, Japanese, Portuguese, and Spanish translations - making news of advances in the field available to pediatric and neonatal intensive care practitioners worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信